MONTREAL, QUEBEC -- (MARKET WIRE) -- April 25, 2007 -- Mistral Pharma Inc. (TSX VENTURE: MIP) (“Mistral”) updated investors today on its product pipeline during the BioFinance conference in Toronto. Mr. Bertrand Bolduc, President & CEO of Mistral stated: “The last year has been quite positive for Mistral and its pipeline products have progressed well. We have entered into exclusive discussions with a strategic partner for MIST-B01 for the co-development and commercialization of our product for the US market. We hope to conclude a definitive agreement in the coming months. MIST-B02 has showed positive results in its first pilot study. Mistral is initiating discussions with potential development partners. MIST-B03 will be the subject of a first pilot PK trial in the third and fourth quarters of 2007. If the results are positive, business development activities will also be initiated for MIST-B03" he concluded.
